Recent trends in the treatment of testosterone deficiency syndrome.
Testosterone deficiency syndrome (TDS) is defined as a clinical and biochemical syndrome associated with advancing age and is characterized by typical symptoms and deficiency in serum testosterone levels. TDS is a result of the interaction of hypothalamo-pituitary and testicular factors. Now, treatment of TDS with testosterone is still controversial due to a lack of large, controlled clinical trials on efficacy. The risks of treatment with testosterone appear to be minimal, although long-term studies on the safety of testosterone therapy are lacking. The aim of the therapy is to establish a physiological concentration of serum testosterone in order to correct the androgen deficiency, relieve its symptoms and prevent long-term sequelae. All of the available products, despite their varying pharmacodynamic and pharmacokinetic profiles, are able to reach this goal. Newer testosterone patches seem not to cause severe skin irritation. Testosterone gels minimize the skin irritation while providing flexibility in dosing and a low discontinuation rate. Oral testosterone undecanoate (TU) is free of liver toxicity. Recent formulation of oral TU markedly increased shelf-live, a major drawback in the older preparation. Producing swings in testosterone levels rising rapidly to the supraphysiological range is not the case with the new injectable long-acting preparation of TU. To be able to rapidly react and stop treatment in cases where side-effects and contraindications are detected, the short-acting transdermal and oral delivery modes have certain advantages. However, there is no evidence that the use of an injectable long-acting TU in men with TDS has limitations in clinical application for this reason. The use of dehydroepiandrosterone is still controversial because of a lack of well designed long-term trials, although some recent studies suggest positive effects on various body systems. Only a few studies have been carried out to investigate the effect of hCG (human chorionic gonadotropin) in TDS with some positive results on various body systems.
Hong
Bum Sik
BS
Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Poongnap-dong, Sonpa-gu, Seoul, Korea.
Ahn
Tai Young
TY
D000375:Aging; D000728:Androgens / Q000627:therapeutic use*; D001823:Body Composition; D004359:Drug Therapy, Combination; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D053580:Muscle Strength; D010024:Osteoporosis / Q000517:prevention & control; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D013577:Syndrome; D013739:Testosterone / Q000031:analogs & derivatives* / Q000097:blood / Q000172:deficiency* / Q000627:therapeutic use
D000728:Androgens; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D013739:Testosterone; D000068677:Sildenafil Citrate; C010792:testosterone undecanoate